PAION
DEAD

Serial Number

78070532

Owner

Paion Deutschland GmbH

Attorney

GARY D. KRUGMAN

First Use Date

Feb 1, 2005

Filing Date

Jun 22, 2001

Add to watchlist:

No watchlists yet
View on USPTO

PAION Trademark

Serial Number: 78070532 • Registration: 3134824

PAION is a trademark filed by Paion Deutschland GmbH on June 22, 2001. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Paion Deutschland GmbH (11 trademarks)

Martinstr. 10-12
52062 Aachen , DE

Entity Type: 99

PAION GmbH (4 trademarks)

Kaiserplatz 5
Stolberg 52222 , DE

Entity Type: 03

Trademark Details

Filing Date

June 22, 2001

Registration Date

August 29, 2006

First Use Anywhere

February 1, 2005

First Use in Commerce

February 1, 2005

Published for Opposition

June 6, 2006

Cancellation Date

April 7, 2017

Goods & Services

[ (Based on Use in Commerce) Educational services, namely, providing seminars, informational events and/or workshops in the field of biotechnology, pharmacology, biochemistry, molecular biology, medical procedures, product research and development of medical devices and pharmaceutical preparations, research procedures, protein design diagnostics, molecular diagnostics, proteogenomic profiling, gendiagnostics ]

(Based on 44(e)) Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment [ and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, ] nervous diseases, [ diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; ] medical and clinical diagnostic reagents for clinical or medical laboratory use

[ (Based on 44(e)) Computerized database management, namely, editing, evaluating and processing data for third parties ]

(Based on 44(e)) Reagents for scientific or medical research use; diagnostic preparations or reagents for scientific or research use, biochemical reagents for scientific or medical research use; biochemical diagnostic preparations or reagents for scientific or research use

[ (Based on 44(e)) Laboratory devices for medical and pharmaceutical investigations, namely, portable medical devices for conducting medical diagnostic tests and blood specimen analysis of the human blood clotting system; medical devices, namely, coated catheters, medical stents, surgical implants comprising artificial materials; membranes intended for medical use, namely, filters for dialysis, hemofiltration ]

(Based on 44(e)) [ Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; ] preparation of expert opinions in the field of [ chemical engineering, biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, ] product research and development of medical devices and pharmaceutical preparations; [ and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; ] performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; [ bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment; ] scientific research on and development of [ medical diagnostic equipment and ] pharmaceutical preparations and products for the treatment of [ tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, ] nervous diseases, [ diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, ] pain [ and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA-microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment ]

Filing History

CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Apr 7, 2017 CAEX
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Aug 29, 2015 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Mar 14, 2013 NA85
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 14, 2013 C15P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 14, 2013 APRE
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
Feb 27, 2013 815F
TEAS SECTION 8 & 15 RECEIVED
Feb 27, 2013 E815
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 15, 2006 ASGN
REGISTERED-PRINCIPAL REGISTER
Aug 29, 2006 R.PR
PUBLISHED FOR OPPOSITION
Jun 6, 2006 PUBO
NOTICE OF PUBLICATION
May 17, 2006 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Apr 14, 2006 PREV
ASSIGNED TO LIE
Apr 7, 2006 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 6, 2006 CNSA
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Apr 6, 2006 ZZZX
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 6, 2006 CNSA
USE AMENDMENT ACCEPTED
Apr 6, 2006 IUAA
AMENDMENT FROM APPLICANT ENTERED
Mar 28, 2006 ACEC
AMENDMENT FROM APPLICANT ENTERED
Mar 28, 2006 ACEC
AMENDMENT TO USE PROCESSING COMPLETE
Mar 28, 2006 AUPC
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 14, 2006 CRFA
USE AMENDMENT FILED
Mar 14, 2006 IUAF
PAPER RECEIVED
Mar 14, 2006 MAIL
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 9, 2006 CRFA
PAPER RECEIVED
Mar 9, 2006 MAIL
NON-FINAL ACTION MAILED
Jan 30, 2006 CNRT
NON-FINAL ACTION WRITTEN
Jan 30, 2006 CNRT
PREVIOUS ALLOWANCE COUNT WITHDRAWN
Jan 30, 2006 ZZZX
1(B) BASIS DELETED; NEW BASIS REQUESTED
Jan 24, 2006 ADBS
NOTICE OF ALLOWANCE CANCELLED
Jan 24, 2006 IUCN
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Dec 22, 2005 PCBG
PETITION TO DIRECTOR - CHANGE BASIS - RECEIVED
Nov 18, 2005 PDCB
PAPER RECEIVED
Nov 18, 2005 MAIL
SOU EXTENSION 5 GRANTED
Sep 15, 2005 EX5G
SOU EXTENSION 5 FILED
Sep 1, 2005 EXT5
PAPER RECEIVED
Sep 1, 2005 MAIL
SOU EXTENSION 4 GRANTED
Apr 18, 2005 EX4G
SOU EXTENSION 4 FILED
Mar 9, 2005 EXT4
PAPER RECEIVED
Mar 9, 2005 MAIL
SOU EXTENSION 3 GRANTED
Sep 28, 2004 EX3G
SOU EXTENSION 3 FILED
Sep 8, 2004 EXT3
PAPER RECEIVED
Sep 8, 2004 MAIL
CASE FILE IN TICRS
Aug 11, 2004 CFIT
SOU EXTENSION 2 GRANTED
Mar 23, 2004 EX2G
SOU EXTENSION 2 FILED
Mar 8, 2004 EXT2
PAPER RECEIVED
Mar 8, 2004 MAIL
SOU EXTENSION 1 GRANTED
Oct 8, 2003 EX1G
DIVISIONAL PROCESSING COMPLETE
Oct 8, 2003 DPCC
SOU EXTENSION 1 FILED
Sep 9, 2003 EXT1
DIVISIONAL REQUEST RECEIVED
Sep 9, 2003 DRRR
PAPER RECEIVED
Sep 9, 2003 MAIL
NOA MAILED - SOU REQUIRED FROM APPLICANT
Mar 11, 2003 NOAM
PUBLISHED FOR OPPOSITION
Dec 17, 2002 PUBO
NOTICE OF PUBLICATION
Nov 27, 2002 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 15, 2002 CNSA
ASSIGNED TO EXAMINER
Oct 1, 2002 DOCK
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 22, 2002 CRFA
PAPER RECEIVED
Aug 22, 2002 MAIL
FINAL REFUSAL MAILED
May 9, 2002 CNFR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 19, 2001 CRFA
NON-FINAL ACTION MAILED
Sep 17, 2001 CNRT
ASSIGNED TO EXAMINER
Aug 24, 2001 DOCK